Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma that arises from the nasopharynx.
8 clinical trials registered, 4 recruiting. Interventions under study include procedural interventions, drug therapy, biologic therapy, and other interventions. Pipeline includes 4 PHASE2, 2 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06662058](https://clinicaltrials.gov/study/NCT06662058) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation |
NA |
Emory University |
RECRUITING |
[NCT06868433](https://clinicaltrials.gov/study/NCT06868433) | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | PHASE1 | Emory University | RECRUITING |
[NCT05245682](https://clinicaltrials.gov/study/NCT05245682) | Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | EARLY_PHASE1 | Emory University | ACTIVE_NOT_RECRUITING |
[NCT07135804](https://clinicaltrials.gov/study/NCT07135804) | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | PHASE2 | Second Affiliated Hospital of Nanchang University | NOT_YET_RECRUITING |
[NCT05063552](https://clinicaltrials.gov/study/NCT05063552) | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
13 publications have been identified in PubMed for nasopharyngeal squamous cell carcinoma. Research spans Case Report / Case Series (62%), Review / Meta-Analysis (23%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 62% |
Research summaries | 3 | 23% |
Clinical study results | 1 | 8% |
Disease patterns and progression | 1 | 8% |
Baliton M (2026). [PMID: 42042797](https://pubmed.ncbi.nlm.nih.gov/42042797/). *Vaccines (Basel)*. [Review / Meta-Analysis]
Denizmen Zorba D (2026). [PMID: 40590065](https://pubmed.ncbi.nlm.nih.gov/40590065/). *Clin Nucl Med*. [Case Report / Case Series]
Chen JN (2026). [PMID: 41839521](https://pubmed.ncbi.nlm.nih.gov/41839521/). *BMJ Case Rep*. [Case Report / Case Series]
Li Y (2026). [PMID: 41562654](https://pubmed.ncbi.nlm.nih.gov/41562654/). *Eur J Cancer Prev*. [Epidemiology / Natural History]
Alsoghier A (2025). [PMID: 39833441](https://pubmed.ncbi.nlm.nih.gov/39833441/). *Lasers Med Sci*. [Clinical Trial Publication]
Lin YW (2025). [PMID: 36345713](https://pubmed.ncbi.nlm.nih.gov/36345713/). *Ear Nose Throat J*. [Review / Meta-Analysis]
Shah IB (2025). [PMID: 40727173](https://pubmed.ncbi.nlm.nih.gov/40727173/). *Indian J Otolaryngol Head Neck Surg*. [Review / Meta-Analysis]
Tang W (2025). [PMID: 40370643](https://pubmed.ncbi.nlm.nih.gov/40370643/). *Oncol Lett*. [Case Report / Case Series]
Albilali A (2025). [PMID: 40823081](https://pubmed.ncbi.nlm.nih.gov/40823081/). *Front Oncol*. [Case Report / Case Series]
Suekata Y (2025). [PMID: 40889202](https://pubmed.ncbi.nlm.nih.gov/40889202/). *Auris Nasus Larynx*. [Case Report / Case Series]
AI-curated news mentioning nasopharyngeal squamous cell carcinoma
Updated Mar 16, 2026
A recent study highlights the association of anti-Hu paraneoplastic syndrome with gastrointestinal dysmotility in patients suffering from nasopharyngeal squamous cell carcinoma and small bowel adenocarcinoma. This research contributes to the understanding of paraneoplastic syndromes and their impact on gastrointestinal function.